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Abstract
Background: HIV-1 RNA plasma concentration at viral set-point is associated not only with disease outcome but also with
the transmission dynamics of HIV-1. We investigated whether plasma HIV-1 RNA concentration and CD4 cell count at viral
set-point have changed over time in the HIV epidemic in the Netherlands.
Methodology/Principal Findings: We selected 906 therapy-naı ¨ve patients with at least one plasma HIV-1 RNA
concentration measured 9 to 27 months after estimated seroconversion. Changes in HIV-1 RNA and CD4 cell count at
viral set-point over time were analysed using linear regression models. The ATHENA national observational cohort
contributed all patients who seroconverted in or after 1996; the Amsterdam Cohort Studies (ACS) contributed
seroconverters before 1996. The mean of the first HIV-1 RNA concentration measured 9–27 months after seroconversion
was 4.30 log10 copies/ml (95% CI 4.17–4.42) for seroconverters from 1984 through 1995 (n=163); 4.27 (4.16–4.37) for
seroconverters 1996–2002 (n=232), and 4.59 (4.52–4.66) for seroconverters 2003–2007 (n=511). Compared to patients
seroconverting between 2003–2007, the adjusted mean HIV-1 RNA concentration at set-point was 0.28 log10 copies/ml
(95% CI 0.16–0.40; p,0.0001) and 0.26 (0.11–0.41; p=0.0006) lower for those seroconverting between 1996–2002 and
1984–1995, respectively. Results were robust regardless of type of HIV-1 RNA assay, HIV-1 subtype, and interval between
measurement and seroconversion. CD4 cell count at viral set-point declined over calendar time at approximately 5 cells/
mm
3/year.
Conclusion: The HIV-1 RNA plasma concentration at viral set-point has increased over the last decade of the HIV epidemic in
the Netherlands. This is accompanied by a decreasing CD4 cell count over the period 1984–2007 and may have implications
for both the course of the HIV infection and the epidemic.
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Introduction
During the asymptomatic phase of HIV-1 infection, virus
production and clearance are believed to reach a balance reflecting
a relatively stable level of HIV-1 RNA concentration in plasma.
Whether this balance, or viral set-point, is reached in all patients
remains open to debate [1,2]. It is agreed, however, that with a higher
HIV-1 RNA plasma level, progression to AIDS is more frequent [3],
as is the rate of HIV-1 transmission [4]. A rising trend over time in
plasma HIV-1 RNA concentration at set-point might imply an
increase in the efficiency of transmission [5,6]. Three observational
studies found no evidence for such a change [7–9], whereas two
studies did [10,11]. Contrasting results likewise come from studies of
HIV-1 RNA replicative fitness at viral set-point, thought to be
positively correlated with HIV-1 RNA concentration in plasma
[12,13]. One study suggested a lower replicative fitness in HIV-1
isolates obtained from patients infected in 2002–2003 compared to
isolates from patients infected between 1986–1999 [14], but samples
were not matched for time since seroconversion. A similar study,
using isolates obtained from participants of the Amsterdam Cohort
Study and samples matched for time since seroconversion, found an
increase in replicative fitness over time [15].
Here we present a study of changes in the mean HIV-1 RNA
concentration and CD4 cell count at viral set-point measured in
patients who became seropositive between 1984 and 2007.
Results
Baseline characteristics of the included 906 patients are
summarized in Table 1. CD4 cell counts were available for 811
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contact recorded as the most likely transmission route, and 82%
originated from W-Europe/N-America. Most patients from other
regions of origin were from S-America/Caribbean. Only 2% were
from sub-Sahara Africa.
Results of HIV-1 subtyping, using nucleotide sequences of the
pol region obtained for HIV-1 drug-resistance testing, were
available for 449 (50%) patients, and subtype B was found in
408 (91%). Infection with circulating recombinant form (CRF)
02_AG was found in 15 patients, CRF 01_AE in 8, subtype A in 5,
Table 1. Baseline characteristics.
Estimated 1984–1995 year of 1996–2002 seroconversion 2003–2007 Total
Total 163 232 511 906
MSM from W-Europe/N-America, excluding non-B subtype 114 (71%) 143 (61%) 355 (66%) 612 (68%)
Gender
Male 144 (88%) 206 (89%) 480 (94%) 830 (92%)
Transmission risk group
MSM 119 (73%) 162 (70%) 410 (80%) 691 (76%)
Heterosexual 3 (2%) 49 (21%) 54 (11%) 106 (12%)
IDU 22 (13%) 7 (3%) 2 (0%) 31 (3%)
Other 17 (11%) 12 (5%) 18 (4%) 47 (5%)
Unknown 2 (1%) 2 (1%) 27 (5%) 31 (3%)
Region of origin
W-Europe/N-America 134 (82%) 188 (81%) 420 (82%) 742 (82%)
Other 5 (3%) 40 (17%) 75 (15%) 120 (13%)
Unknown 24 (15%) 4 (2%) 16 (3%) 44 (5%)
Subtype
B 59 (36%) 76 (33%) 273 (53%) 408 (45%)
Non-B 1 (1%) 8 (3%) 32 (7%) 41 (5%)
Sample not available 103 (63%) 148 (64%) 206 (40%) 457 (50%)
Resistance-associated mutation found
At least one mutation 7 (4%) 5 (2%) 20 (4%) 32 (4%)
None 46 (28%) 78 (34%) 269 (53%) 393 (43%)
Sequence not available 110 (67%) 149 (64%) 222 (43%) 481 (53%)
Sensitivity of assay
Standard 163 (100%) 104 (45%) 42 (8%) 309 (34%)
Sensitive 0 114 (49%) 443 (87%) 414 (46%)
Unknown 0 14 (6%) 26 (5%) 40 (4%)
Amplification technique of assay
NASBA 163 (100%) 53 (23%) 44 (9%) 260 (29%)
bDNA 0 66 (28%) 175 (34%) 241 (27%)
RT-PCR 0 99 (43%) 266 (5%) 265 (29%)
Unknown 0 14 (6%) 26 (5%) 40 (4%)
HBV
Negative 59 (36%) 201 (87%) 431 (84%) 691 (76%)
Positive 3 (2%) 14 (6%) 24 (5%) 41 (5%)
Unknown 101 (62%) 17 (7%) 66 (11%) 184 (20%)
HCV
Negative 44 (27%) 188 (81%) 397 (78%) 629 (69%)
Positive 9 (6) 10 (4%) 20 (4%) 39 (4%)
Unknown 110 (67) 34 (15%) 94 (18%) 238 (26%)
Age at seroconversion in years median, (IQR) 34.4 (28.9–40.5) 33.8 (29.9–40.4) 36.4 (30.0–43.1) 35.2 (29.8–41.7)
Months between seroconversion and plasma HIV-1 RNA
measurement, median (IQR)
11.6 (10.1–14.5) 10.9 (9.9–12.7) 10.9 (9.8–12.4) 10.9 (9.9–12.8)
Months between seroconversion and CD4 cell count
measurement, median (IQR)
10.3 (10.0–11.1) 10.7 (9.8–12.2) 10.6 (9.7–11.9) 10.5 (9.8–11.8)
doi:10.1371/journal.pone.0007365.t001
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and CRF 03_AB in 1 patient. Of 425 patients tested before
antiretroviral therapy was started, 32 (7.5%) had at least one
resistance mutation.
In all 163 patients with seroconversion before 1996, the HIV-1
RNA concentration at set-point was measured with assays using
the NASBA technique. Overall, RT-PCR was most used (in 40%
of the 906 total). HIV-1 RNA plasma concentrations measured at
set-point were below the lower quantitation limit of the assay used
in 37 of 906 (4%) patients. In 19 patients (2%), HIV-1 RNA
concentrations were above the upper quantitation limit of the
assay used.
The mean HIV-1 RNA concentration at set-point in all 906
patients was 4.45 log10 copies/ml. It was 4.30, 4.27, and
4.59 log10 copies/ml in patients with an estimated seroconversion
date between 1984–1995, 1996–2002, and 2003–2007, respec-
tively. Table 2 shows the differences in mean HIV-1 RNA
concentration according to estimated year of seroconversion, as
obtained with unadjusted and adjusted regression models.
Compared to patients with an estimated seroconversion date in
or after 2003, the adjusted mean HIV-1 RNA concentration
among patients seroconverting between 1996 and 2002 and before
1996 was lower by 0.29 log10 copies/ml (95% CI 0.16–0.41;
p,0.0001) and 0.27 (0.12–0.42; p=0.0004), respectively. Fur-
thermore, the adjusted mean HIV-1 RNA concentration at set-
point was 0.32 (95% CI 0.12–0.51) log10 copies/ml lower in
women compared to men (p=0.002). Patients infected with
subtype B had on average a 0.40 (0.14–0.67) log10 copies/ml
higher HIV-1 RNA concentration (p=0.003) than patients
infected with non-B subtypes. The mean HIV-1 RNA concentra-
tion was 0.16 (0.00–0.32) log10 copies/ml higher in patients from
W-Europe/N-America compared to patients from elsewhere
(p=0.04). There were no significant differences in mean HIV-1
RNA concentration according to age at seroconversion (p=0.43),
HIV transmission group (p=0.95), interval between seroconver-
sion and viral set-point (p=0.96), or presence of a resistance
mutation (p=0.92).
To test whether the increase in viral set-point could reflect
changing use of various quantitative HIV-1 RNA assays over time,
we added type of assay to the model. The differences in mean
HIV-1 RNA concentration between different periods of serocon-
version increased slightly (Table 2). Relative to seroconverters
between 2003 and 2007, the mean HIV-1 RNA concentration was
0.31 log10 copies/ml (95% CI 0.18–0.44; p,0.0001) lower for
seroconverters between 1996 and 2002 and 0.40 (0.18–0.63;
p=0.0003) lower for those seroconverting before 1996. The
difference in HIV-1 RNA concentration measured with RT-PCR
assays was on average 20.12 log10 copies/ml (95% CI 20.30,
0.07; p=0.21) compared to NASBA assays and 0.04 (20.09, 0.17;
p=0.54) compared to bDNA assays. The HIV-1 RNA concen-
Table 2. Mean (95% CI) differences in HIV-1 RNA concentration at viral set-point (log10 copies/ml) according to time of
seroconversion.
Plasma HIV-1 RNA
concentration First 9–27 months
after
seroconversion at 12 months at 18 months at 24 months
Patient group All patients
Homogeneous
patient group
a
Homogeneous
patient group
a
Homogeneous
patient group
a
Homogeneous
patient group
a
N 906 612
b 552
c 370
c 315
c
Unadjusted model Year of seroconversion
2003–2007 (reference) 0.00 0.00 0.00 0.00 0.00
1996–2002 20.32 (20.45, 20.20) 20.44 (20.59, 20.29) 20.45 (20.61, 20.29) 20.35 (20.54, 20.15) 20.39 (20.62, 20.16)
p,0.0001 p,0.0001 p,0.0001 p=0.0005 p=0.0008
1984–1995 20.29 (20.44, 20.15) 20.37 (20.54, 20.20) 20.37 (20.54, 20.20) 20.38 (20.61, 20.15) 20.32 (20.54, 20.10)
p,0.0001 p,0.0001 p,0.0001 p=0.001 p=0.008
Adjusted model Year of seroconversion
2003–2007 (reference) 0.00 0.00 0.00 0.00 0.00
1996–2002 20.29 (20.41, 20.16) 20.41(20.67, 20.27) 20.42 (20.58, 20.26) 20.33 (20.53, 20.13) 20.39 (20.62, 20.16)
p,0.0001 p,0.0001 p,0.0001 p=0.001 p=0.0008
1984–1995 20.27 (20.42, 20.12) 20.34 (20.51, 20.17) 20.34 (20.51, 20.17) 20.37 (20.60, 20.13) 20.32 (20.54, 20.10)
p=0.0004 p,0.0001 p,0.0001 p=0.002 p=0.005
Adjusted model
also including
type of assay
Year of seroconversion
2003–2007 (reference) 0.00 0.00 0.00 0.00 0.00
1996–2002 20.31 (20.44, 20.18) 20.44(20.60, 20.28) 20.46 (20.62, 20.29) 20.34 (20.54, 20.13) 20.37 (20.61, 20.13)
p,0.0001 p,0.0001 p,0.0001 p=0.001 p=0.0008
1984–1995 20.40 (20.63, 20.18) 20.55 (20.82, 20.29) 20.60 (20.87, 20.32) 20.40 (20.76, 0.03) 20.32 (20.74, 0.11)
p=0.0003 p,0.0001 p,0.0001 p=0.002 p=0.005
aHomogeneous patient group: MSM from W-Europe/N-America. Patients with non-B subtype infection excluded.
bAdjusted for gender, region of origin, subtype, age at seroconversion, HIV transmission group, interval between seroconversion and viral set-point, and presence of a
resistance mutation.
cAdjusted for availability of subtype data.
doi:10.1371/journal.pone.0007365.t002
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p=0.10) higher when measured with the NASBA technique
compared to samples tested with assays using bDNA. HIV-1 RNA
concentration measured using assays with a lower detection limit
#400 copies/ml was 0.08 log10 copies (95% CI 20.24, 0.08;
p=0.33) lower than those measured using assays with a higher
detection limit. However, the differences according to calendar
year of seroconversion remained similar. Also, when analyses were
stratified according to the type or sensitivity of the assay, results
remained similar (results not shown).
Given scarce data on HCV or HBV co-infection in patients who
seroconverted before 1996, we restricted analyses including such
co-infections as a confounder to the 743 patients who serocon-
verted in or after 1996. Mean HIV-1 RNA concentration in
patients with a HCV co-infection was 0.36 log10 copies/ml (95%
CI 0.08–0.64, p=0.01) higher than in patients without a HCV co-
infection. It was 0.09 log10 copies/ml (20.1620.35, p=0.46)
higher in patients with a HBV co-infection compared to patients
without. Differences in mean HIV-1 RNA concentration accord-
ing to year of HIV-1 seroconversion remained similar, being
0.29 log10 copies/ml (0.17–0.41, p,0.0001) higher in patients
with seroconversion between 2003–2007 compared to 1996–2002.
To avoid any bias arising from changes in the distribution of
ethnicity, gender, and infection with non-B subtype over time, we
focused on a homogeneous patient group of 612 MSM from W-
Europe/N-America. Patients with a confirmed HIV-1 non-B
infection were excluded. Figure 1 shows the HIV-1 RNA
concentration at set-point and at 12, 18, and 24 months after
seroconversion and the estimated mean HIV-1 RNA concentra-
tion by calendar year of seroconversion. The dashed line in
Figure 1a shows that the mean set-point HIV-1 RNA concentra-
tion at the start of 1985 was 4.46 log10 copies/ml (95% CI 4.27–
4.65). It was 4.21 log10 copies/ml (4.09–4.33) at its lowest value in
1995 and 4.88 log10 copies/ml (4.76–5.01) in 2007. Estimates of
differences in mean HIV-1 RNA concentration at set-point
according to the calendar year of seroconversion for this subgroup,
shown in Table 2, are similar to those for the total of 906 patients.
HIV-1 subtype was the only variable included in the adjusted
model apart from estimated year of seroconversion. On further
restricting the sample size to the 297 patients known to be infected
with subtype B, we found similar differences in mean HIV-1 RNA
concentration (results not shown). Finally, we looked separately at
plasma HIV-1 RNA levels at 12, 18, and 24 months after
seroconversion and found mean HIV-1 RNA concentrations of
4.50, 4.48, and 4.40 log10 copies/ml, respectively. Differences in
mean HIV-1 RNA concentration at 12 and 18 months according
to estimated year of seroconversion were similar to those obtained
through models including the first HIV-1 RNA concentration
between 9 and 27 months after seroconversion. In a final
sensitivity analysis, including 751 patients with a maximum
Figure 1. HIV-1 RNA concentration at viral set-point and mean HIV-1 RNA concentration at each time period. In MSM patients from W-
Europe or N-America with a proven or likely infection with subtype B: a) first HIV-1 RNA 9–27 months after seroconversion (n=612), b) at 12 (n=552),
c) 18 (n=370), and d) 24 months (n=315). The solid black line shows the mean HIV-1 RNA concentration for patients with an estimated date of
seroconversion from 1984 through 1995, 1996 through 2002, and 2003 through 2007 (as shown in Table 2). Dashed black lines are estimates obtained
by continuous modelling of the estimated date of seroconversion using cubic splines.
doi:10.1371/journal.pone.0007365.g001
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RNA concentration taken after seroconversion was 0.48
log10 copies/ml (95% CI 0.26–0.71; p,0.0001) lower for
seroconverters before 1996 and 0.17 (0.00–0.35; p=0.05) lower
between 1996–2002 compared to 2003–2007. The mean was
0.31 log10 copies/ml (0.06–0.56; p=0.02) lower for seroconver-
ters before 1996 compared to 1996–2002.
In 811 patients with CD4 cell counts available between 9–27
months after seroconversion, the median count at viral set-point
was 520 cells/mm
3 (IQR 390–680). Table 3 shows results of the
linear regressions of CD4 cell count at viral set-point. Mean CD4
cell count at viral set-point declined throughout the period 1984–
2007 by 0.025 cube root cells/mm
3/year (95% CI 0.012, 0.038;
p,0.0001), a decline of approximately 5 CD4 cells/mm
3/year.
Region of origin was the only other variable included in the
adjusted model. Mean CD4 cell count at viral set-point in patients
from W-Europe/N-America with seroconversion between 2003–
2007 was 507 cells/mm
3 (485–530), compared to 466 cells/mm
3
(425–509, difference p=0.07) for patients from elsewhere. Table 3
shows results of regression analyses of CD4 cell count on a cube-
root scale for our homogeneous patient group. The mean decrease
over time of the first CD4 cell count 9–27 months after
seroconversion and at 12, 18, and 24 months after seroconversion
was 0.028 (95% CI 0.014, 0.041), 0.025 (0.011, 0.038), 0.027
(0.013, 0.041), and 0.021 (0.004, 0.038) cubic root cells/mm
3/
year, respectively. Figure 2 shows the estimates back-transformed
to the original scale. Mean CD4 count at 12 months was 592 (562–
653), 563 (523–605) and 502 cells/mm
3 (479–527) for serocon-
verters between 1984–1995, 1996–2002, and 2003–2007, respec-
tively. Estimated differences in CD4 count between seroconverters
of 1996–2002 and 2003–2007 were greater in analyses of the
homogeneous patients than in analyses of the total group.
Discussion
We found a rising trend over time in the HIV-1 RNA
concentration at set-point in patients infected in the last decade,
with a complementary downward trend in CD4 cell count at viral
set-point.
Our results agree with those of the CASCADE study [10] and a
recent study of the epidemic in Italy [11]. The CASCADE study
found an increase in mean HIV-1 RNA concentration at viral set-
point of 0.035 log10 copies/ml/year over the period 1985–2002,
although we found an increase only from 1996. Three other
studies found no evidence for an increase [7–9]. Differences in
patient selection, study period, and outcome definitions across
these five studies might explain the discrepancies. In a study from
the Swiss HIV Cohort Study (SHCS) and the Italian cohort study
[8,11], all patients with a confirmed HIV-1 infection were selected.
Other studies restricted patient selection to seroconverters with a
maximum seroconversion interval of 6 months [9] or 12 months
[7,10]. Herbeck et al. [7] looked at HIV-1 RNA concentration at
set-point in 384 homosexual patients with known seroconversion
dates between 1985 and 2005, but most were infected before 1996.
The study period in that study and the SHCS [8] might have been
too short to find an increase in HIV-1 RNA concentration at set-
point over time. Outcome definitions of the five studies ranged
from the first available measurement of HIV-1 RNA plasma
concentration after seroconversion [9,10] to measurements at a
later stage [7,8,11]. Because the exact moment of seroconversion is
unknown, the former definition has the disadvantage of not
knowing whether the measurement was taken during the peak
HIV RNA concentration phase following infection, during the
phase shortly before or after the peak, or during the set-point
phase. This type of measurement error most likely hampers the
detection of significant changes over time. Admittedly, using
measurements at a later stage can introduce bias, because patients
who have started antiretroviral therapy early are censored from
the analysis. Assuming that patients with a high HIV-1 RNA
concentration and a low CD4 cell count will start therapy earlier
than patients with a lower concentration and a higher cell count,
results may be biased towards a lower HIV-1 RNA concentration
and higher CD4 cell count at viral set-point from 1996 onwards,
especially in measurements taken 24 months after seroconversion.
Table 3. Changes (95% CI) in CD4 cell count at viral set-point (cells/mm
3) using different models.
CD4 cell count First 9–27monthsafter seroconversion at 12 months at 18 months at 24 months
Patient group All patients All patients
Homogeneous
patient group
a
Homogeneous
patient group
a
Homogeneous
patient group
a
Homogeneous
patient group
a
Unadjusted Adjusted
b
N 811 811 578 555 439 347
Median CD4 cell count, (cells/mm
3) 520 520 530 530 490 480
Change in CD4 cell count at viral
set-point (cubic cells/mm
3/year)
20.025 (20.038,
20.012)
20.026 (20.039,
20.013)
20.028 (20.041,
20.014)
20.025 (20.038,
20.011)
20.027 (20.041,
20.013)
20.021 (20.038,
20.004)
p,0.0001 p=0.0001 p,0.0001 p=0.0004 p=0.0002 p=0.02
Difference in mean CD4 cell count
(cube root cells/mm
3)
2003–2007 (reference) 0.00 0.00 0.00 0.00 0.00 0.00
1996–2002 0.18 (20.01, 0.37) 0.19 (20.01, 0.38) 0.31 (0.08, 0.54) 0.31 (0.07, 0.54) 0.50 (0.25, 0.76) 0.27 (20.05, 0.59)
p=0.07 p=0.06 p=0.008 p=0.01 p,0.0001 p=0.10
1984–1996 0.43 (0.20, 0.65) 0.45 (0.21, 0.68) 0.51 (0.26, 0.76) 0.45 (0.20, 0.70) 0.49 (0.24, 0.74) 0.35 (0.05–0.65)
p=0.0002 p=0.0002 p,0.0001 p=0.0004 p=0.0001 p=0.02
aHomogeneous patient group: MSM from W-Europe/N-America. Patients with non-B subtype infection excluded.
bAdjusted for gender, region of origin, subtype, age at seroconversion, HIV transmission group, interval between seroconversion and viral set-point, and presence of a
resistance mutation.
doi:10.1371/journal.pone.0007365.t003
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patients who seroconverted before 1996 and those who did so
between 1996 and 2002 with respect to the first HIV-1 RNA
concentration after seroconversion and no significant difference
when analysing the first HIV-1 RNA concentration taken 9–27
months after seroconversion. However, both analyses showed an
increasing HIV-1 RNA concentration over time.
The decreasing trend in CD4 cell count at viral set-point over
time complements the increasing trend in HIV-1 RNA concen-
tration. A similar decrease in CD4 cell count over time was
likewise found in other studies [10,16,17]. Evidence of an
increasing trend [18] or a stable level [7,19] in CD4 cell count
might reflect a shorter study period.
Bias through systematic inclusion of correlated transmission
networks is unlikely, as active enrolment of related partners was
never in place during our entire study period. Other potential
sources of bias which could have influenced our finding include
the genetic heterogeneity of HIV-1, which can impede the
accuracy of quantitation, especially in early assays primarily
designed to detect subtype B [20–22]. However, the effect
persisted when we focused on a homogeneous group of MSM
from W-Europe/N-America with a proven or highly likely subtype
B infection. The higher mean HIV-1 RNA concentration in
patients for whom we lacked subtype data points to some residual
confounding because of infection with non-B subtypes. However,
sensitivity analyses of patients known to be infected with subtype B
found similar differences in mean HIV-1 RNA concentration at
set-point over time.
Disease progression has been shown to differ among patients
with subtype A, C, D and G infection [23–25]. We found a higher
mean HIV RNA concentration in patients with subtype B
infection compared to non-B, as well as in patients from W-
Europe/N-America compared to those with other origins. A
recent study reported a higher set-point virus load in patients with
white ethnicity compared to black (mostly from sub-Sahara
Africa), but no significant differences between infection with B
and non-B subtypes [26]. Differences in the distribution of
ethnicity and subtypes might explain this discrepancy.
Since only 30 of the 830 men we studied were infected through
heterosexual contact, lack of power might have been a reason we
found a non-significant difference in HIV RNA concentration at
set-point between MSM and heterosexually infected patients. The
SHCS reported a significant difference between MSM and
heterosexually infected patients [8]. Also in contrast to the SHCS,
ourstudy and others found a higherHIV RNAconcentrationat set-
point in female patients. The difference in HIV RNA concentration
between men and women emerges only at lower CD4 cell counts
[27], a factor that could explain these different results.
Figure 2. CD4 cell count at viral set-point and mean CD4 cell count at each time period. In MSM from W-Europe/N-America with a proven
or likely subtype B infection: a) first CD4 cell count between 9 and 27 months after seroconversion (n=578), b) at 12 months (n=555), c) 18 months
(n=439), and d) 24 months (n=347). The solid black line shows the mean CD4 cell count for patients with an estimated date of seroconversion from
1984 through 1995, 1996 through 2002, and 2003 through 2007 (as shown in Table 2). The dashed black lines were obtained using linear models
assuming a constant decrease between 1984 and 2007.
doi:10.1371/journal.pone.0007365.g002
Increasing Set-Point HIV-1 RNA
PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7365The HIV-1 RNA plasma concentration was measured with
several assays. The distribution of the assays used has changed
over the years, and we did not perform batch-wise re-testing of
samples using only one assay. HIV-1 RNA concentrations
measured within the dynamic range of the Versant HIV-1 RNA
(bDNA) 3.0 assay are, on average, lower than those measured with
the Cobas Amplicor assay (RT-PCR) [28–30]. The Amplicor
HIV-1 Monitor assay (RT-PCR) [31] yields, on average, lower
concentrations than the NASBA HIV-1 RNA QT assay, the only
assay used in samples taken before 1996. This ranking was
reflected in our analyses and might explain the more pronounced
differences after adjusting for type of assay between seroconverters
from 1984–1995 and from 2003–2007. In concordance with
previous reports, the mean HIV-1 RNA concentration at set-point
was slightly higher when measured using assays with a lower
detection limit of 1000 or 400 copies/ml compared to #50 cop-
ies/ml [32], but adjustment for assay sensitivity did not
appreciably change our results. The changing distribution of
assays is thus unlikely to explain the increase in mean HIV-1 RNA
concentration at viral set-point over time.
Techniques for measuring CD4 cell counts changed over time
as well, leading to less test variability. Absolute CD4 cell counts
were traditionally assessed using a dual-platform technique that
has been gradually replaced by a single-platform technique
introduced in the late 1990s. Others changes in flow cytometry
techniques over time include changes in the gating strategy and
sample preparation. There is some evidence to suggest that CD4
cell counts turn out lower when measured using the single-
platform technique. Also, CD45-SSC gating, more frequently used
in later calendar years, may yield higher CD4 cell counts than
CD45-CD14 gating, more frequently used in earlier calendar
years [33]. For our study, these two potential biases may outweigh
each other.
In samples obtained before 1996, quantitation followed storage
at 280uC. No significant effect of freezing, storage, and thawing
on HIV RNA recovery using the Amplicor HIV-1 Monitor and
NASBA HIV-1 RNA QT assay has been reported [31,34,35].
Moreover, we observed an increase in mean HIV-1 RNA
concentration at set-point between periods 1996–2002 and
2003–2007.
The awareness level of physicians and patients to symptoms of
acute HIV-1 infection has improved in recent years and could
have influenced our findings. Set-point HIV-1 RNA concentration
has been shown to increase with the number of symptoms after
recent HIV-1 infection [36,37]. In times when patients without
symptoms were overlooked, the mean HIV-1 RNA concentration
at set-point was most likely overestimated. However, as data on
symptoms were not collected, we could not investigate this further.
The increasing number of patients included in our study over
time positively correlated with increasing set-point viral load levels.
The contribution of resulting selection of higher viral load at set-
point in to facilitating the spread of HIV is a cause for alarm.
However, other reasons for the higher number of study patients in
more recent years include more sexual risk behaviour [38,39],
more HIV-negative subjects who repeatedly test for sexually
transmitted infections (STIs) [39–41], and a higher incidence of
STIs [42]. Also, the start in 2003 of a randomized study of patients
with primary HIV-1 infection has raised physician awareness.
Therefore, the higher number of new infections in recent years
included in our study cannot be ascribed solely to a higher set-
point viral load in those years. As for the other possibility, an
ongoing phylogenetic study has found no indications that newly
imported HIV-1 strains are responsible for the changes in set-point
HIV RNA levels.
Some evidence suggests that HIV-1 RNA concentration at viral
set-point is an adaptive trait and may change under the influence
of selection [6]. Transmission of HIV-1 is thought to happen most
efficiently very early, during primary infection, and late, during the
symptomatic phase [4,43]. During the asymptomatic phase after
primary infection, the probability of transmission may be smaller,
but given the long duration of this phase, its contribution to the
number of newly infected patients is probably substantial.
Successful antiretroviral therapy, usually started some years after
primary infection, suppresses HIV-1 RNA plasma concentration
to levels at which the probability of transmission is considered
minimal. Thus the period of infectiousness may largely be
confined to the very early phase of infection, in which viruses
that reproduce at a high level are selected. Such viruses could
establish a high HIV-1 RNA concentration at set-point in a new
host [44]. For this hypothesis to hold, set-point viral load between
transmitter and recipient needs to be correlated. This correlation
will be investigated in a future study, using data from transmission
networks.
A significant increase in HIV-1 replication fitness over time has
been described for the Amsterdam epidemic [15]. Follow-up
molecular analysis should reveal which changes in the viral
components are responsible for this increased replication capacity.
An increase in HIV RNA concentration at set-point may be also
the result of adaptation of HIV to particular HLA molecules in the
population. Kawashima et al. show that HLA molecules associated
in 1983 with slow disease progression did not protect against
disease progression in Japanese patients infected between 1997–
2008 [45].
In conclusion, we found an increase in the HIV-1 RNA plasma
concentration measured at viral set-point and a decrease in CD4
cell count in non-treated patients with a confirmed HIV-1
seroconversion during the last decade of the HIV epidemic in
the Netherlands. The higher HIV-1 RNA concentration could not
be attributed to changes in subtype or assay used, but coincides
with a higher proportion of treated HIV-1-infected patients. The
implications of an increased HIV-1 RNA concentration at viral
set-point on disease progression and on transmission dynamics
require further study.
Methods
Patient selection
The ATHENA observational cohort [46] includes anonomyzed
data from all HIV- infected patients living in the Netherlands who
receive care in one of the 24 HIV treatment centres. Initially, data
were collected only from patients who had started combination
antiretroviral therapy (cART). Data collection was extended in
2002 to include all HIV-infected patients, cART treated or
untreated alike, who had been followed since 1996 in any of the
centres. ATHENA patients are informed by their treating
physician of an opt-out procedure. Ethical approval is not
obtained, as data collection is part of HIV care. For our study,
we also included data obtained from homosexual men (MSM)
participating in the Amsterdam Cohort Studies (ACS) [47].
Informed written consent is obtained from all ACS participants,
and the ACS has been approved by the Medical Ethical
Committee of the Academic Medical Centre.
We selected patients with a maximum interval of one year
between the last negative and first positive HIV-1 antibody test.
The day of seroconversion was estimated as the midpoint between
the last seronegative and the first seropositive test. Patients with
negative or indeterminate Western Blot results in the presence of
HIV-1 p24 anitigen or RNA were also selected, in which case the
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first positive antibody test. All patients in our study were at least 16
years old at the estimated day of seroconversion, had been
sampled at least once for plasma HIV-1 RNA concentration
between 9 and 27 months after seroconversion, and were
antiretroviral therapy-naive. All patients who seroconverted before
1996 were participants of the ACS.
Measurements
First, we used the HIV-1 RNA concentration and CD4 cell
count measured in peripheral blood sampled earliest in the 9–27
months after seroconversion as the measurements at viral set-
point. In addition, we selected results of the HIV-1 RNA and CD4
cell count measurements taken between 9 and 15 months (closest
to 12), between 15 and 21 months (closest to 18), and between 21
and 27 months (closest to 24). Any measurements taken after the
start of antiretroviral therapy were not used in any analysis. Assays
were classified according to the amplification technique: nucleic
acid sequence-based amplification (NASBA), reverse transcriptase-
polymerase chain reaction (RT-PCR), and branched DNA signal
amplification (bDNA). Assays using the NASBA technique were
NASBA HIV-1 RNA QT, NucliSens HIV-1 RNA QT, and
NucliSens EasyQ (bioMe ´rieux, Boxtel, The Netherlands). Assays
using RT-PCR techniques were Amplicor HIV-1 Monitor, Cobas
Amplicor, Cobas TaqMan HIV-1 (Roche Diagnostics, Pleasanton,
CA, USA), LCx HIV RNA quantitative, and m2000rt HIV RNA
(Abbott, Abbott Park, IL, USA). The only assay using the bDNA
technique was Versant HIV-1 RNA version 3.0 (Siemens,
Deerfield, IL, USA). Classification by amplification technique is
very similar to classification by manufacturer. The RT-PCR assays
made by Roche and Abbott were grouped together. Since the
Abbott assay was used in only 59 patients who all seroconverted in
2006 and 2007 these assays could not be analysed separately.
Finally, HIV-1 RNA assays were also classified as standard (having
a lower detection limit of 1000 or 400 copies/ml) and sensitive
(having a lower detection limit #50 copies/ml).
Statistical analysis
Parametric survival regression models with a normal error
distribution were used to model changes in plasma HIV-1 RNA
concentration at set-point. When below the limit of detection, the
value was regarded as interval-censored between 1 copy/ml and
the lower detection limit. Values above the upper detection limit
were right-censored at the upper detection limit. CD4 cell count at
viral set-point was modelled using linear regression models. CD4
cell counts were cube root-transformed to apply better to model
assumptions. Estimated calendar year of seroconversion was
modelled using 3 categories: ,1996 (pre-cART), 1996–2002 and
$2003. The post-cART cut-off was chosen so that each time
period was sufficiently wide and included a sufficient number of
patients. Estimated date of seroconversion was continuously
modelled using restricted cubic splines with knots at the 5
th,5 0
th
and 95
th percentiles. This allowed us to model date of
seroconversion in a flexible manner and to avoid having to report
results over year categories with few patients. Splines with 5 knots
were also used but led to similar estimates. Potential confounders
for analysis of HIV-1 RNA concentration at set-point included
gender, region of origin (W-Europe/N-America, other, and
unknown), age at seroconversion, HIV-1 subtype (B, non-B, and
unknown), transmission of drug-resistant virus (at least one
mutation, none, and unknown) [48], interval between measure-
ment and seroconversion, transmission risk group (men having sex
with men [MSM], heterosexual, intravenous drug use [IDU],
other, and unknown), co-infection with HBV of HCV (positive,
negative, or unknown), sensitivity of assay (lower detection limit
$400 and ,400 copies/ml), and technique of the quantitative
HIV-1 RNA assay used (NASBA, RT-PCR, and bDNA). Active
HBV co-infection was defined as a positive HBsAg test. Chronic
HCV co-infection was defined as a positive HCV RNA test or, if
not available, a positive HCV antibody test. We used the first
available test result up to 2 years after the estimated HIV-1
seroconversion date. Variables were retained in adjusted models if
their overall p-value was ,0.20.
To obtain results in a population as homogeneous as possible,
we also ran models including only data from MSM from W-
Europe/N-America. Patients with a proven HIV-1 non-B
infection were excluded. If the HIV-1 subtype was not determined,
patients were included. In addition, we performed sensitivity
analyses on patients with a confirmed subtype B infection. A final
sensitivity analysis was performed on patients with a maximum
seroconversion interval of 6 months, using the first HIV-1 RNA
measurement after seroconversion as dependent variable. This
analysis was performed in order to study the potential bias that
results from censoring patients with an early start of antiretroviral
therapy. Models were adjusted for time between the estimated day
of seroconversion and the measurement using restricted cubic
splines.
Analyses were performed using SAS version 9.1 (SAS Institute,
Cary, North Carolina, USA).
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